Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2026 / April / ASCRS 2026: New Data Highlight Performance of TECNIS PureSee EDOF IOL
News Latest Research & Innovations

ASCRS 2026: New Data Highlight Performance of TECNIS PureSee EDOF IOL

New data highlight visual outcomes and patient experience

4/10/2026 2 min read

Share

  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Poll
  • Top Institutions
5 Key Takeaways
  • 1

    Johnson & Johnson will present new data on the TECNIS PureSee EDOF IOL at the 2026 ASCRS Annual Meeting in Washington, DC.

  • 2

    The TECNIS PureSee lens is designed to extend vision range beyond standard monofocal lenses while maintaining contrast sensitivity.

  • 3

    A US clinical trial showed the lens provides strong distance vision and improved intermediate performance compared to a monofocal control.

  • 4

    Post-market studies indicated high patient satisfaction, with 96% achieving distance spectacle independence and low visual disturbance rates.

  • 5

    Johnson & Johnson will also present additional data on the TECNIS platform, highlighting high spectacle independence and low dysphotopsia rates.

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: